GRTXD · Galera Therapeutics, Inc.
$18.99
At close · Aug 3
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern through the 12 months from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed May 14, 2026
Market Cap
$15.23M
Shares
802,149
Volume · Aug 3
2447
Avg daily vol (6 sessions)
1267
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.99
Open$16.00
Day$16.00–19.00
52W close$3.20–20.96
Avg vol 30d590
Short int25 · 0.0% float · 1.0d
Short vol35%
Last earningsAug 10, 2023
DataJan 2020–Aug 2026
Filing10-Q · May 14
Up next
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+92%
above
Price vs 50-day avg
+2%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+332%
trailing
YTD return
+332%
this year
Relative strength
+322%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -7.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 5-yr low, contrarian setup
Fundamentals
EPS growth
+288%
Y/Y
Free cash flow
$-6.0M
Valuation
P/E 0.2
below peers
Quant / Vol
risk profile
Volatility
143%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+92%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -7.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 5-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3
Now $19 · 89%
Range high $21
vs 200-day avg +92%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRTXD
this stock
Galera Therapeutics, Inc.
|
$15.23M | — | — | 0.2 | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Ascentis Independent Advi…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRTXD | +14.7% | +10.8% | +331.6% | +21.6% | +331.6% |
| SPY | +2.5% | +0.9% | +9.2% | +1.4% | +11.1% |
| vs SPY | +12.2% | +9.9% | +322.4% | +20.2% | +320.5% |